Literature DB >> 11944603

Lung cancer: a review.

Robert J Cersosimo1.   

Abstract

The frequency, risk factors, pathophysiology, diagnosis, and management of lung cancer are reviewed. An estimated 157,400 Americans died of lung cancer in 2001. Lung cancer is the second most frequent cancer in both men and women. The major risk factor for lung cancer is smoking, which accounts for 75-80% of lung cancer-related deaths. Lung cancers can be broadly classified into two forms, small-cell carcinomas and non-small-cell carcinomas. Non-small-cell lung cancer is more common, accounting for up to 75% of lung cancers. Lung cancer is diagnosed by chest radiography, sputum cytology, bronchoscopy, needle biopsy, and other techniques. Surgery plays a major role in managing stage I and stage II non-small-cell lung cancer and may be used for stage III disease. Patients with stage IIIa disease may be surgical candidates, but involvement of mediastinal lymph nodes reduces the probability of survival. Adjuvant irradiation may reduce the rate of local recurrence but does not increase survival time. Adjuvant chemotherapy may confer a small survival-time advantage if the regimen includes cisplatin. Chemotherapy combined with radiation therapy may produce a survival advantage over irradiation alone. Patients with advanced non-small-cell lung cancer should receive combination chemotherapy. Several regimens have shown a survival advantage over best supportive care. Paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan have activity both as single agents and in combination. Surgery has only a limited role in the management of small-cell lung cancer. Patients with limited disease should receive a platinum-based chemotherapy regimen plus radiation therapy. Combination chemotherapy should be offered to patients with extensive disease. The most active regimens contain cisplatin or carboplatin. Paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan combinations have shown some promise. Lung cancer, although highly preventable, is usually diagnosed at an incurable stage. Chemotherapy is playing an increasingly important role alongside surgery and radiation therapy in the management of this disease.

Entities:  

Mesh:

Year:  2002        PMID: 11944603     DOI: 10.1093/ajhp/59.7.611

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  31 in total

Review 1.  HPV infections and lung cancer.

Authors:  K J Syrjänen
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer.

Authors:  Wei Zhao; Jun-Jie Zhao; Long Zhang; Qin-Fu Xu; Yu-Miao Zhao; Xiao-Ya Shi; Ai-Guo Xu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  Gefitinib.

Authors:  Christine R Culy; Diana Faulds
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.

Authors:  Fuquan Zhang; Mingjing Shen; Li Yang; Xiaodong Yang; Ying Tsai; Peter C Keng; Yongbing Chen; Soo Ok Lee; Yuhchyau Chen
Journal:  Cancer Biol Ther       Date:  2017-07-07       Impact factor: 4.742

Review 5.  Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.

Authors:  James E Frampton; Stephanie E Easthope
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification.

Authors:  Gregory J S Lohman; Joanne Stubbe
Journal:  Biochemistry       Date:  2010-02-23       Impact factor: 3.162

7.  Reduced expression of claudin-7 is associated with poor outcome in non-small cell lung cancer.

Authors:  Taketsugu Yamamoto; Takashi Oshima; Kazue Yoshihara; Sumitaka Yamanaka; Teppei Nishii; Hiromasa Arai; Kenji Inui; Takeshi Kaneko; Akinori Nozawa; Tetsukan Woo; Yasushi Rino; Munetaka Masuda; Toshio Imada
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

8.  The pulmonary surfactant: impact of tobacco smoke and related compounds on surfactant and lung development.

Authors:  J Elliott Scott
Journal:  Tob Induc Dis       Date:  2004-03-15       Impact factor: 2.600

9.  Methylation of RILP in lung cancer promotes tumor cell proliferation and invasion.

Authors:  Jianbo Lin; Yi Zhuo; Yinhe Yin; Linbin Qiu; Xu Li; Fancai Lai
Journal:  Mol Cell Biochem       Date:  2020-10-30       Impact factor: 3.396

10.  MicroRNA-4491 enhances cell proliferation and inhibits cell apoptosis in non-small cell lung cancer via targeting TRIM7.

Authors:  Fei Han; Gang Chen; Yi Guo; Bo Li; Yanlong Sun; Xiangqian Qi; Hanji Tian; Xinfei Zhao; Hongguang Zhang
Journal:  Oncol Lett       Date:  2021-06-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.